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Abstract
Disruptions in DNA repair pathways predispose cells to accumulating DNA damage. A growing
body of evidence indicates that tumors accumulate progressively more mutations in DNA repair
proteins as cancers progress. DNA repair mechanisms greatly affect the response to cytotoxic
treatments, so understanding those mechanisms and finding ways to turn dysregulated repair
processes against themselves to induce tumor death is the goal of all DNA repair inhibition efforts.
Inhibition may be direct or indirect. This burgeoning field of research is replete with promise and
challenge, as more intricacies of each repair pathway are discovered. In an era of increasing
concern about healthcare costs, use of DNA repair inhibitors can prove to be highly effective
stewardship of R&D resources and patient expenses.
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Capitalizing on differences between cancerous and noncancerous cells to find more effective
therapeutic solutions is an area of ongoing, intense research. Defects in DNA and/or DNA
repair can cause cancer as well as promote its growth. As cancers become increasingly
mutagenic, genetic streamlining leads to deficiencies in one or more DNA repair pathways –
accompanied by compensatory activities that increase the levels of certain repair proteins in
the same pathway or a different one [1]. This contributes to intrinsic or acquired cellular
resistance to DNA-damaging agents [2]. Interrupting DNA repair in such a way that shuts
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down a tumor's compensatory repair mechanisms and induces cell death is the goal of all
research surrounding DNA repair inhibition.
DNA repair inhibitors, particularly small-molecule inhibitors, hold great promise for
damaging tumor cells. Their specificity can be honed to target a single step or single protein
of a DNA repair pathway. Achieving that goal moves us closer to truly personalized
medicine. However, the development of such inhibitors is offset by several real-world
challenges.
Research has amassed much data regarding DNA repair protein(s) that are under- or over-
expressed in cancers – but which ones do the cancers themselves uniquely require? In a
perfect world, one altered gene or gene product would create a unique footprint that
corresponded to just one repair pathway or would drive a rate-limiting or saturable reaction.
Unfortunately, finding a target that fulfils that wish list is the exception, rather than the rule.
A mutagenic phenotype is rarely the result of one under- or over-expressed protein, and
molecular pathogenesis is not linked to an isolated step in oncogenic progression. In
addition, the multifunctionality of many DNA repair proteins can complicate inhibition
efforts with unexpected results. Pathways are complex and crosstalk between pathways
occurs (Table 1) [3–5]. As mutagenesis increases, greater tumor heterogeneity from
crosstalk and compensation further complicates identification of viable targets for inhibition.
Finally, the relative lack of biomarkers to help sort this out is not unlike driving in uncharted
territory without a map. Research is in its infancy in corralling the collective contributions of
multiple proteins that constitute a mutagenic phenotype.
Inhibition & synthetic lethality
Because preserving the genome is paramount, DNA repair is replete with alternate plans. If
one pathway fails to repair a problem, another pathway can step in (Table 1) [3–5]. While
that elegant plan helps maintain genomic stability under normal circumstances, it contributes
to chemoresistance when repair mechanisms go awry. However, if the alternative pathway
contains a mutation that makes the pathway dysfunctional or nonfunctional, then impairing a
step in the main pathway can force repairs into the backup mode where repair will fail,
causing the cells to self-destruct. That is the principle of synthetic lethality, and PARP
inhibition is the leader in that principle.
PARP's primary activity is in the base excision repair (BER) pathway, where it gauges the
extent of damage and functions as a scaffold or stabilizer for other BER proteins. PARP
inhibition abrogates BER functionality, causing accumulation of unresolved single-stranded
breaks (SSBs) that convert to double-stranded breaks (DSBs) during S phase. Because
BRCA-deficient cancer cells cannot repair DSBs via the homologous recombination (HR)
repair pathway, they attempt to so do via the error-prone nonhomologous end joining
(NHEJ) pathway. However, recombinogenic lesions and other errors cause the collapse of
replication forks and cell death when NHEJ attempts the repairs [7,8].
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Successes & bumps in the road
The concept of `treating a weakness' to create a synthetic lethality [9] was launched in 2005
when two seminal papers demonstrated that PARP inhibitors (PARPis) could be used as
single agents to treat BRCA-deficient cell lines [8]. The first clinical study that
demonstrated the benefit of the PARPi olaparib as monotherapy in BRCA−/− patients was
presented in 2007; final results were published in 2009 [10]. PARP's stunning success
against BRCA1 and BRCA2 breast cancers led to an explosion of research surrounding
PARP inhibition, including a quest for its use in broader clinical applications (Table 2).
Since then, a plethora of clinical trials have studied PARPis both as monotherapy and
combination therapy. However, in early 2011, that research suffered two blows.
First, a Phase III trial of iniparib (BSI-201) to treat metastatic, triple-negative breast cancer
(TNBC) failed to prolong patient survival, despite promising Phase II trial results [12].
TNBC is clinically and pathologically similarity to BRCA1/2-mutated breast cancers in that
both have very aggressive profiles, poor prognosis and limited treatment options [13].
Subsequently, Phase III development of olaparib (AZD-2281) to treat hereditary BRCA1-
and BRCA 2-associated breast cancer was halted [7,14].
These seeming `failures' spawned greater scrutiny of both the products themselves as well as
protocol criteria. Iniparib was deemed technically not to be a PARPi but rather a cysteine-
binding poison (and is still being pursued as a chemotherapeutic). Heavily pretreated patient
cohorts and the phenotypical heterogeneity of some cancers, particularly TNBC, were
deemed to have contributed to differences observed in Phase II versus III testing, as well as
variations in patient outcomes within the same trial. Ultimately, this led to a redoubled effort
to learn more about PARP's precise mechanisms of action and a redirection of some clinical
trials in what patient populations to target [13].
Lessons learned from PARPis
The ups and downs of intense PARP research are helping scientists identify and anticipate
bumps in the road for developing targeted inhibitors in general. To summarize, science has
learned that:
• PARP proteins are not solely involved in DNA repair. They also play roles in
transcription, telomere replication, cellular transport, NF-κB regulation and HSP90
expression [15,16]. Hints at those (and yet-to-be discovered) functions are seen
outside PARP's catalytic region. Although the catalytic domain is conserved among
all 18 members of the PARP family, dissimilarities in PARP's automodification
domain and DNA binding domain distinguish each PARP from one another [10];
• PARPis do more than bind the catalytic domains of PARP1 and PARP2. Because
PARP1 has multiple domains that bind DNA damage, enzymatic activity can, in
theory, be blocked without interfering with the catalytic site itself and without
affecting essential functions of other PARP family members. This could increase
specificity and decrease treatment side effects [13];
• Not all PARPis are created equal. PARP must be inhibited by >90% to detectably
inhibit DNA repair [17]. However, some PARPis work on tumors that are resistant
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to other kinds of PARPis. For example, AZD2461 (first Phase I trial recently
completed) shows clinical activity on olaparib-resistant tumors [18]. This is due in
part to, but cannot be fully explained by, structural differences. First- and second-
generation PARPis are nicotinamide analogs, benzamides or substituted
benzamines; their specificity and potency vary greatly. Many third-generation
PARPis are derived from the 3-aminobenzamide structure; others are polycyclic
lactams; most are competitive inhibitors [10,16]. Ongoing research into the
structural and mechanistic aspects of PARP will hopefully clarify the reasons for
these differences;
• The `poisoning potency' of a PARPi depends on its strength in stabilizing PARP-
DNA complexes – irrespective of the compound's catalytic inhibition. Thus, the
extent to which PARP trapping occurs has a greater clinical effect on cell killing
than enzymatic inhibition of PARP activity [19,20]. This is one plausible
explanation for why various PARPis perform differently, even on the same cohort
of patients [16];
• The synthetic lethality that PARP inhibition confers (capitalizing on a weakness in
the HR repair pathway) is not limited to BRCA1- and 2-deficient cancers;
• Genetic deficiencies that confer high sensitivity to PARPis include deficiencies in
XRCC2, XRCC3, RAD54 and H2AX [20]. Cancers containing PTEN1 and ATM
deficiencies and microsatellite instabilities (as seen in colorectal cancers) also
respond well to PARPis [16].
These discoveries not only fuel the fire for broader therapeutic applications [16]; they also
provide clues regarding how to approach the development and use of other types of DNA
repair inhibitors.
Double-edged sword of inhibiting multifunctional repair proteins
PARP proteins, like many other DNA repair proteins, are multifunctional. That
characteristic cuts both ways. While inhibiting a multi-functional protein can affect multiple
pathways and theoretically increase its tumor-killing ability, it may produce unanticipated
results and/or increased toxicities.
Similar challenges and opportunities exist with checkpoint proteins, the sentries of DNA
damage response. Due to their ubiquitous nature and multitasking abilities, inhibiting them
could either cause great good or great harm – unless research can pinpoint how and when
such inhibition would have the greatest therapeutic effect. For a full discussion of
checkpoint inhibitors as monotherapy or combination therapy, see [21].
Overview of each pathway & inhibitors in development
Direct repair pathway
The direct repair (DR) pathway is unique in that only one protein is involving in performing
a solitary, nonenzymatic process that repairs instead of replacing a damaged base. The sole
protein involved, MGMT, removes one alkyl group from the O6 position of a damaged
guanine base, such as generated by treatment with the clinical alkylating agent
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temozolomide (TMZ), and transfers it to an internal Cys residue in MGMT. The non-
reversible reaction, which is greatest before late G1 [22], culminates with inactivation and
degradation of the MGMT molecule. The stoichiometric reaction is driven by cells' ability to
continually make more MGMT. To a lesser extent, MGMT performs the same function on
the O4 position of thymine. Without MGMT repair, alkyl adducts would cause thymine
mispairings during replication, leading to erroneous G:C-to-A:T transitions or strand breaks
– necessitating the recruitment of other pathways to perform more complex repairs [3].
Overactivity of MGMT is responsible for chemoresistance; for example, >90% of recurrent
gliomas show no response to a second cycle of chemotherapy. Conversely, inhibition of
MGMT renders cancer cells sensitive to TMZ. Addtionally, MGMT promoter alkylation is a
significant determinant in the sensitivity of drugs such as TMZ. There is abundant evidence
linking the methylation of the MGMT promoter to loss of protein expression resulting in
increased sensitivity to chemotherapeutic agents and to the prognostic outcome of patients
treated. However, the role of MGMT promoter methylation in tumorigenesis and its utility as
a prognostic bio-maker still needs further attention. Similarly, low MGMT expression
appears to be a biomarker for slower tumor progression [22].
DR inhibitors in development & on the market
Many compounds initially thought to be MGMT inhibitors have proved to be checkpoint
inhibitors instead. Only one true MGMT inhibitor, O6 benzylguanine (O6-BG), is currently
on the market. In vitro studies of O6-(4 bromothenyl) guanine (PaTrin-2 or PAT), a
pseudosubstrate inactivator of MGMT, show greater potency than O6-BG. However, it
causes dose-limiting toxicities when administered with TMZ [23].
More novel approaches to MGMT inhibition are also being tried (Box 1) [22,24–27]. A
Phase I trial of extended low-dose administration of TMZ to deplete MGMT prior to
standard TMZ dosing is showing promise for patients previously resistant to TMZ.
Oncolytic viruses (Adenovirus E1A protein, mutant HSV G207) show preclinical activity in
inhibiting MGMT transcription [22]. For more details on MGMT inhibitors in development,
see [22].
Base excision repair
The BER pathway corrects single-base (nonhelix-distorting) damage caused by oxidation,
alkylation, deamination and ionizing radiation (IR). If left unchecked, such damage would
cause incorrect base pairings that would become mutagenic if transcribed [4]. BER consists
of two subpathways; the activation of one or the other is predicated by first the cause and
type of damage, second the type of abasic (apurinic, apyrimidinic) (AP) site generated in the
first repair step [4] and third the cell cycle phase in progress when the damage occurs [29].
The short-patch pathway quickly repairs single-base damage during the G1 phase; the long-
patch pathway handles lengthier repairs during S or G2, when resynthesis of two to eight
nucleotides surrounding the AP site is required [29]. For details of BER pathway
mechanisms, see [30].
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Alkylating agents, platinating agents, cytotoxic antibiotics and taxanes create DNA lesions
that the BER pathway normally repairs [31]. Thus, BER inhibition holds promise for
potentiating the effects of those treatments. Inhibitors of four BER proteins that are either
unique to this pathway, have very specific BER functions or are otherwise attractive
candidates for inhibition are in development: APE1, Pol β, FEN1 and PARP (Table 3) [32–
39].
APE1 is the only DNA repair protein that also regulates reduction-oxidation (redox)
activities. Its redox functions affect DNA repair indirectly and influence many transcription
factors involved in cancer promotion and progression [34]. In the repair process, APE1
activity creates special ter-mini to prepare the abasic site so that a polymer-ase can insert the
correct resynthesized base [40]. APE1's redox functions help maintain transcription factors
in a reduced, activated state so they can fold properly, bind to DNA and produce proteins the
cells need. APE1 does this directly through a thiol/sulfite exchange and indirectly through a
`redox chaperone' function that is still being characterized [31].
APE1 overexpression confers chemo- and radio-resistance [31] and is associated with
shorter time to progression and poorer prognosis [34]. APE1 is dysregulated or upregulated
in many solid cancers, including hepatocellular, prostate, pancreatic, ovarian, cervical, germ
cell tumor, rhabdomyosarcoma and colon cancers [4,31,38]. Many other characteristics of
APE1 make it a highly desirable target for inhibitor development. APE1's diverse activities
offer multiple opportunities for inhibitor development to modulate multiple repair and
signaling pathways that represent multiple cancer survival mechanisms [4,38,41–42].
In preclinical studies, blockade of APE1's repair functions potentiates the cell-killing
abilities of many anticancer agents, including methyl methane sulfonate (MMS), H2O2,
bleomycin, TMZ, melphalan, cisplatin, IR and gemcitabine [4,43–44]. Blockade of APE1's
redox functions has numerous antiproliferative and antiangiogenic effects [41,43–45].
Redox inhibition also alters the tumor microenvironment, including downregulation of
HIF1α, AP-1 and NF-κB [34]. Treatment with an APE1 redox inhibitor could prevent DNA
binding of cytokine signaling. Very recent study results show that blockade of APE1's redox
function blocks phosphorylation (and thus transcription) of STAT3 [46]. Thus, treatment
with a STAT3 inhibitor (which directly blocks the DNA binding region of STAT3) plus an
APE1 redox inhibitor has been demonstrated to cause synthetic lethality in human
pancreatic and glioblastoma cell lines. A bonus is that APE1 redox blockade controls the
signaling crosstalk that occurs between the tumor and the tumor micro-environment [34,46].
This could eventually provide a new treatment paradigm for hard-to-treat cancers.
BER inhibitors in development & on the market
Inhibitors of both APE1's repair and redox functions are in various stages of preclinical
development. Some inhibitors originally touted to be specific for APE1 have turned out to
be more properly `BER inhibitors' because they bind to the aldehyde of the AP site on DNA.
An example is methoxyamine (MX, or TRC102). However, MX continues to be studied as a
component of combination treatment for a variety of cancers. At the time of this writing, one
Phase I trial had been completed and three more were in progress [47]. Other nonspecific
APE1 inhibitors are actually topoisomerase poisons [48]. A number of investigators have
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identified several specific APE1 repair inhibitors; however, research has not yet progressed
much past the cell culture stage [36–38,49–51].
E3330 and newer analogs show promise for specifically inhibiting APE1's redox functions.
Initial indications are that these will be used in adults and children with acute lymphoblastic
leukemia and other cancers [52].
The second BER protein that is a candidate for inhibition is Pol β. It is an attractive target
for inhibition for three reasons: it performs both DNA resynthesis and removal of the
blocking 5′-deoxyribose-5-phosphate (5′-dRP) residue in both short- and long-patch BER;
its associated lyase activity is often rate-limiting in BER; and it is upregulated in many
cancers, which contributes to resistance to IR, bleomycin, monofunctional alkylating agents
and cisplatin [31].
Research into scores of potential inhibitors showed that early candidates lacked specificity.
Interestingly, four naturally occurring compounds (oleanolic acid, edgeworin, betulinic acid
and stigmasterol) appear to affect DNA repair only – not scheduled replicative activity [39].
However, none of those compounds are very potent.
Two new compounds, NCS-666715 and NSC-124854, show high potency at very low
concentrations. Both are being evaluated in murine models as chemosensitizers for
colorectal cancers. Notably, both can block both short- and long-patch BER without
affecting APE1, FEN1 or DNA Ligase I activity, which theoretically would minimize
collateral damage to healthy cells. Studies to date show that combining TMZ with either of
these compounds blocks the growth of both mismatch repair (MMR)-proficient and MMR-
deficient colon cancer cells in vitro and causes antitumor activity in vivo [33,35].
Although the NCS compounds are far from moving into clinical trials, they underscore the
interactivity of multiple DNA repair pathways – and how the research of DNA repair
inhibitors must adopt a broader `systems' approach because of that. Many colon tumors
become resistant to alkylating agents, either due to MGMT overexpression, MMR
deficiency or both. Both BER and MMR can repair mismatch pairs and other alkylation
adducts that DR (MGMT) does not repair. However, if BER is inhibited and 8-oxoguanine
(8-oxoG) adducts accumulate, the damage becomes lethal to cells deficient in the MMR
proteins MLH1 or MSH2.
FEN1 is critical to DNA repair and replication. FEN1 is the major human endonuclease that
recognizes and cleaves 5′ DNA flaps in long-patch BER; it also removes Okazaki primers in
lagging strand DNA synthesis – approximately 50 million per cell cycle [53]. To perform
this endonuclease function imprecisely or inefficiently results in DNA that is not ligatable,
which delays cell replication and necessitates postreplicative repairs that endanger genomic
stability [53].
FEN1 is elevated in many cancers, including gastric, lung, prostate, pancreatic, breast and
brain cancers [53]. Cell studies demonstrate that lack of the FEN1 gene makes cells
hypersensitive to alkylating agents [31]. All these reasons make FEN1 an attractive target
for inhibition. Although its potential for broad therapeutic application has been likened to
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that of PARP [54], development of any FEN1 inhibitors is in only the very earliest stages, as
finding specific compounds with inhibitory capacity at nanomolar concentrations has been
elusive (Table 3) [33].
Finally, for BER, many PARPis are already in clinical use; trials are ongoing for second-
and third-generation PARPis, as discussed earlier in this article [3,16].
Mismatch repair
The MMR pathway is the cell's main repair mechanisms for correcting base–base
mismatches and repairing insertion and/or deletion loops formed during DNA replication
[55]. Before the damage can become permanent or duplicated in future cell cycles, MMR's
postreplicative damage control removes the DNA immediately surrounding the mismatch
and replaces it with a newly synthesized segment copied from the daughter strand as a
template. The MSH2–MSH6 complex attends to the repair of base substitutions and small
mismatched loops, while the MSH2–MSH3 complex repairs both small loops and large-loop
mismatches. Varying recognition complexes are formed based on the type of mismatch to be
repaired. Notably, the repair is completed specifically on the new strand [55].
Deficiencies in MMR increase mutation rates in cells up to 1000-fold [55,56]. Mutations in
four MMR genes (MSH2, MLH1, PMS2 and MSH6) predispose cells to a range of cancers,
including hereditary nonpolyposis colon cancer [55]. However, up to 20% of sporadic
cancers are due to MMR defects as well [57].
MMR inhibitors in development
Paradoxically, impaired MMR functionality fosters damage tolerance, which contributes to
increased mutagenicity, tumor heterogeneity and chemoresistance [56]. One way to exploit
the lack of one or more MMR genes is to create a synthetic lethality – to ensure that the
damage is truly beyond repair. Studies showing that a high accumulation of oxidative stress
induced in MMR-deficient cells can create such a synthetic lethality. A Phase II clinical trial
is underway to test the efficacy of methotrexate on MSH2-deficient cells [55,58]. Cell
studies show that a Pol β inhibitor can create a synthetic lethality in MSH2-deficient cells.
Similarly, a Pol γ inhibitor can create a synthetic lethality in cells lacking MSH2 (Table 4)
[55,59]. Both polymerase inhibitors create an abundance of 8-oxoG lesions [60]. The BER
pathway would normally repair such oxidative lesions; but because those polymerase
inhibitors would also affect BER, a synthetic lethality is created.
MMR proficiency increases cells' sensitivity to alkylating agents, antimetabolites and
fluoropyrimidines by 2- to 100-fold – enabling other cellular processes to arrest the cell
cycle in G2 and later trigger cell death pathways [61]. Because hypermethylation of the
hMLH1 gene promoter reduces promoter expression in many sporadic cancers,
hypomethylation could restore MMR function, sensitizing cells to those classes of
chemotherapeutics. Cell studies of fluoropyrimidine derivative, 5-fluoro-2-deoxycytidine
(FdCyd), have demonstrated this potential utility [57].
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Nucleotide excision repair
NER repairs bulky, helix-distorting lesions caused by UV irradiation and chemical mutagens
that crosslink adjacent purine bases and form intrastrand adducts. Deficiencies in NER
render cells sensitive to platinating agents, which attempt to arrest the cell cycle at G2 [62].
The success of this drug class is demonstrated most dramatically in the 95% cure rate of
testicular cancer treated with cisplatin [63]. However, intact NER activity contributes to
chemoresistance because it can repair damage inflicted by cisplatin, carboplatin and
oxaliplatin [62].
More than 30 proteins compose the NER pathway, four of which appear to be unique to
NER or drive rate-limiting reactions in NER, making those proteins key targets for
inhibition [63]. The XPA protein of NER opens the DNA helix, forming a bubble of
approximately 30 base pairs around the lesion. RPA and XPA stabilize the opened structure
and recruit other proteins to the site, including two endonucleases (XPG and XPF-ERCC1)
to perform the incision step [62–64]. RPA also activates ATR to halt cell cycle progression
[62]. In short, without XPA, NER cannot occur [62–64]. Damaged-strand incision is the
rate-limiting step for the pathway; thus, XPG, XPF, XPA, RPA and ERCC1 are the focus of
virtually all inhibitor research that targets NER. The first three proteins appear to be unique
to NER; ERCC1 has functions in other repair pathways, including HR [64]. For more details
of the mechanisms involving NER activity, see Table 5 and [63].
Mutations at the XPA binding site within ERCC1 can prevent the interaction between the
two proteins; even more notably, this also prevents recruitment of XPF, which normally
binds almost all of its residues to ERCC1. Upstream blockage of ERCC1-XPF activity via
XPA inhibition has been shown to sensitize cancer cells to IR [64].
NER inhibitors in development
As exciting as these findings are, research into NER inhibition is still in early stages – and
most so-called NER inhibitors appear to be rather nonspecific (Table 5) [62,64–65]. One
compound originally thought to be a NER inhibitor (7-hydroxystaurosporine [UCN-01]) is
actually a checkpoint inhibitor [64]. When the current article was written, 19 clinical trials
(seven Phase II; 18 Phase I) had been completed to test UCN-01 as a monotherapy or
combination therapy for a variety of recurrent or relapsed blood-based and solid tumors
[66]. Another compound, F11782, is a topoisomerase I and II inhibitor, but it also appears to
have some capacity to inhibit NER's helicase or incision step [67].
Another compound in clinical trials is trabectedin (also known as Ecteinascidin 743 or
ET-743), which shows activity against the transcription-coupled (TC) NER subpathway
(active during transcription) and HR pathway deficiencies. Although trabectedin's mode of
action is still being elucidated, this alklyloid's DNA binding in the minor groove bends DNA
toward the major groove in a fashion that seems unique to this compound. The net result is
interference with several transcription factors, DNA binding proteins and repair pathways.
Whether direct inhibition of a specific DNA protein occurs is in question. If trabectedin is
specific to TC-NER, then it must affect that subpathway's unique damage sensors (CSA,
CSB). However, to date, that has not been confirmed. We do know that TC-deficient cells
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and XPG-deficient colorectal cancer cells show resistance to trabectedin [68]. At the time of
this writing, 43 clinical trials, including many Phase II trials, were underway for the use of
trabectedin in numerous cancers [69].
MCI13E, a novel isoborneol haloacetate, shows promise in cell studies as an RPA inhibitor
and a sensitizer to platinating agents. Although it irreversibly binds to RPA, the half-life of
this experimental compound is relatively short-lived compared with platinating agents,
which take at least 48 h to produce effects. So, current studies are pursuing a model of
sequential treatment, administering cisplatin 24 h before adding the inhibitor [62].
TDRL-505, a reversible inhibitor that binds to a different site on RPA, is also under study.
Both compounds are still being characterized to determine their mechanisms of action [62].
ERCC1 plays a unique role in NER. It is recruited by XPA, but ERCC1's functionality rests
in its heterodimer form with XPF [65]. The ERCC1–XPF heterodimer excises the damaged
stretch of DNA [33]. Thus, separating the protein–protein interactions of ERCC1 with XPA
and XPF and identifying the domains essential to dimerization are topics of intense research.
Blocking ERCC1–XPF is tantalizing, but the crystal structure for this domain of human XPF
is yet unknown, and a number of endonucleases with similar divalent cation-based cleavage
mechanisms complicate the search for specific inhibitors [70].
In silico models have uncovered a compound, NERI01, which is more flexible and
establishes more hydrogen bonds with ERCC1 than all other compounds that generated to
date from high-throughput screening [65]. Despite the essentially blank slate for ERCC1
inhibitors, research has correlated ERCC1 overexpression with cisplatin resistance [71]; and
ERCC expression is emerging as a predictive biomarker of patients who will respond to
platinum-based chemotherapeutics [64].
Repair of DSBs
A single unrepaired DSB is highly toxic and can lead to aneuploidy, genetic aberrations or
cell death [72]. Such damage can occur naturally when topoisomerases uncoil DNA or be
induced by IR or chemotherapeutics. The most common occurrence is when replication
forks stall and break at the site of unrepaired DNA lesions [28]. Two main pathways repair
DSBs. NHEJ inhibition performs repairs in less than a half hour; in contrast, the time-
intensive work of HR takes many hours [73]. Inhibition of either or both is an important
lynchpin in treating cancers, as unrepaired base damage and SSBs have their last hope for
repair via one of these pathways. However, despite the plethora of repair proteins employed
in each pathway, therapeutic inhibition poses many challenges.
Homologous recombination
The biggest gun in the arsenal of repairing DSBs is HR, as it accurately corrects the most
serious and complicated forms of DSB damage. HR operates predominantly during the S
and G2 phases of the cell cycle so that it can find a large area of homology on a sister
chromatid to use as a template for resynthesizing damaged or lost bases [74,75].
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HR repair can proceed via one of several subpathways [76], but they all follow the same
general steps: resect DNA ends to generate an overhanging area of ssDNA; form a filament
on the end of the overhang to search for a large area of homology on the sister chromatid;
`invade' the filament onto the homologous area; form a DNA heteroduplex (a D-loop),
created from displacing the invading strand; slide or migrate the D-loop to read the area of
homology; extend the overhang as new nucleotides are generated past the original break
point; resolve the Holliday junction that forms as the D-loop pushes along the border
between hetero- and homo-duplex during resynthesis; migrate the repaired ends toward each
other; and restore the duplex strand [28]. For a review of HR and its subpathways, see [72].
HR activity is dysregulated in many cancers. A defect in one or more of its proteins may
impair or upregulate it, or loss of an upstream regulatory protein in another pathway of DNA
damage recognition and repair may cause compensatory HR upregulation. This article has
already discussed how loss of both BRCA1 or 2 alleles impairs HR; to compensate, NHEJ is
used to repair DSBs. However, inhibition of PARP, which is not directly associated with
either DSB repair pathway, can create an accumulation of damage that NHEJ cannot repair –
effectively killing BRCA-deficient cancer cells [76].
Two crucial players in HR are the RPA complex and Rad51. RPA enters early in the repair
process; it stimulates the unwinding of damaged DNA [72,77], then protects and stabilizes
the segment that is resected as a single strand. However, RPA must be replaced by Rad51 in
order for repairs to proceed [72]. Thus, defects, mutations in (or inhibition of) RPA can stall
HR repair [78]. Because RPA has a common cleft for binding many types of proteins, early
efforts are underway to inhibit RPA's protein–protein interactions without perturbing the
binding of RPA to ssDNA [79].
Rad51 initiates strand exchange by complexing with other proteins to form a filament, the
structure that finds and reads an area of homology so the right nucleotides can be
resynethsized to repair the damage [56]. Post-translational modification of mediator proteins
involved in HR repair highly regulate the balance of RPA and Rad51 so that repair is not
inhibited and disassociation does not occur before Rad51's work is complete [72]. Rad51
overexpression is associated with breast and pancreatic cancers, non-small-cell lung cancer
and leukemias [80].
cAbl is a nonreceptor tyrosine kinase that is activated by ATM. As such, it is not truly HR-
specific, but the combination of ATM and cAbl affect Rad51 induction [81].
HR inhibitors in development & on the market
Efforts to modulate dysfunctional HR in malignancies are in their infancy. Many compounds
investigated lack HR specificity. For example, mirin, which inhibits the MRE11–RAD50–
NBS1 (MRN) complex (HR's damage sensor), also inhibits ATM and downregulates NHEJ
[82]. With the exception of RI-1 (which has been tested in cell studies only) [82], small
molecules that directly inhibit specific HR proteins are not in development (Table 6) [80,82–
84].
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Rad51 inhibition can be achieved either by directly blocking its recombinase activity or by
attempting to interfere with Rad51's interactions with other proteins that form the filament.
RI-1 appears to do the former by inhibiting the polymerization of Rad51 onto ssDNA,
which, in turn inhibits monofilament formation. Studies with cancer cell lines indicate RI-1
has a synergistic effect on mitomycin activity. Other potential Rad51 inhibitors appear to
work indirectly: for example, by activating the proapoptopic JNK and p38-MAPK pathways
or by inhibiting ATPase activity. Such compounds have not progressed beyond identifying
them from high-throughput screening of chemical libraries [80].
Three HR-related proteins show promise in indirectly inhibiting HR for anticancer activity:
PARP (already discussed), cAbl and HSP90. Inhibitors of cAbl and HSP90 can arrest the
cell cycle to the point that unrepaired damage triggers apoptosis.
Three classes of cAbl inhibitors exist, their primary distinction being where they bind to the
kinase. Nine kinase inhibitors are currently US FDA approved, but not all of them act on
cAbl [84,85]. Mutations at or distal to the drug-binding site can either cause direct loss of
interaction with the drug or conformational changes that obviate kinase autoinhibition,
respectively. Second-generation inhibitors, including dasatinib and bosutinib, are
overcoming these problems (Table 6). However, a few mutations still do not respond to
those drugs, either; so hybrids of the two drugs are in early development, as are other
compounds that target alternative binding pockets [84].
HSP90 is a molecular chaperone that helps more than 200 proteins fold to their correct
conformation; 48 of those proteins are associated directly with oncogenesis [86]. Inhibition
of HSP90 decreases Rad51 activity and prevents multiple checkpoint proteins from being
activated, both of which can delay cell cycle progression to the point where cumulative
damage triggers apoptosis [83,87]. HSP90 inhibition can simultaneously disrupt tumors'
growth signals, resistance to apoptosis, unregulated replication, neoangiogenesis and tissue
invasion/metastasis [88].
Four classes of HSP90 inhibitors are in development today. Newer analogs of geldamycin,
the first HSP90 inhibitor studied [83], include 17-DMAG, restapimycin (IPI-504), and
tanespimycin. Of the purine and purine-like analogues, PU-H71 is also being tested as a
predictive indicator of tumor dose response [83]. The third class of HSP90 inhibitors is
resorcinol derivatives, including ganetespib, NVP-AUY922, KW-2478 and AT13387.
Finally, SNX-5422, a dihydroindazolone derivative, is in Phase I and II trials (Table 6) [83].
Nonhomologous end joining
NHEJ represents the simplest and fastest mechanism for repairing DSBs [76]. Active
throughout the entire cell cycle but especially in G0/G1, NHEJ directly rejoins the two
severed DNA ends with minimal end processing, regardless of sequence homology. Such
activity may be preferred in G0/G1, as much of the genome is non-coding – and HR's
involvement at those phases could cause deletions, duplications, misalignments and
crossovers [89]. Nonetheless, NHEJ can lose one to 20 nucleotides from either side of the
DSB junction, causing erroneous repair [76]. Interestingly, NHEJ repairs the majority of
damage that IR causes, even though IR damage rarely produces blunt, ligatable DNA [90].
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Investigators have much to learn about NHEJ and its subpathways; however, all forms of
NHEJ follow five general steps: encircle the DNA/detect and tether DSB ends together;
process and remove end groups that cannot be ligated; process ends to make them ligatable;
resynthesize nucleotides; and seal the break [76,86]. For details of all the proteins involved
in NHEJ, see [91]. Within the framework of NHEJ's general steps, proteins in three steps
appear to be unique to that pathway, and, as such, are potential targets for inhibition.
NHEJ inhibitors in development
Like MMR, diminished or defective NHEJ functioning leads to increased risk of cancer,
particularly lymphoid malignancies [92]. Dysfunctional NHEJ also results in damage
tolerance and chemoresistance [76]. Thus, counterintuitively, intact NHEJ function is linked
to better prognosis or treatment response [92]. However, inhibiting NHEJ and thus forcing
cells to perform DSB repair via the more time-intensive HR pathway could induce a
synthetic lethality in HR-deficient tumors. This and other technical issues are hurdles yet to
cross in today's forays into NHEJ inhibition. Indirectly modulating NHEJ activity through
other means may ultimately prove to be at least as effective as a direct approach [92].
Regarding direct inhibition of NHEJ proteins, the most promising candidate is the catalytic
subunit of DNA-PKcs (Table 7) [73,93]. Cells contain an abundance of DNA-PKcs, a
nuclear serine/threonine kinase that is a prerequisite for establishing a functional NHEJ
complex. Through complex autophosphorylations on 20 known sites, DNA-PKcs determines
how/when to engage and disengage from DNA; regulates end access; modulates how
damage is constrained to NHEJ [73]; is involved in telomere protection [94] and interacts
with other DNA repair proteins, including cAbl, HSP90, PARP1 and H2AX, to name a few
[90]. Overexpression of DNA-PKcs correlates with radioresistance in oral squamous cell
carcinoma, lung carcinoma and esophageal cancer [95]. Thus, chemical inhibition of DNA-
PK can enhance HR.
The first foray into DNA-PK inhibition started with wortmannin, a noncompetitive inhibitor
of the related family of PI3Ks. The first nonspecific competitive PI3K inhibitor identified
was LY294002, a morpholine derivative of quercitin [90]. Although its relative instability
and high toxicity did not lend itself to use in humans, NU7441, a more potent and DNA-PK-
specific inhibitor, was developed from it [96]. NU7026 likewise shows similar specificity in
cell studies [94]. However, the only two DNA-PK inhibitors in clinical trials are dual-action
inhibitors that potentially represent two first-in-class drugs. CC-115 is a DNA-PK and TOR
inhibitor; CC-122 is a pleiotropic pathway modulator [11]. Additionally, the oral pan-class I
PI3K inhibitior NVP-BEZ235 is in Phase I/II clinical trials [97].
PNKP, a protein active in NHEJ, processes incompatible termini to prepare them for
nucleotide resynthesis and strand ligation. Interestingly, PNKP can process blunt-ended and
3′-overhanging termini; APE1 is relatively ineffective on the former and cannot process the
latter, so PNKP can handle termini processing that the BER pathway cannot. In addition,
emerging evidence exists for PNKP participation in an APE1-independent form of BER
repair [92]. The one PNKP inhibitor currently being investigated is a polysubstituted
imidopiperidine compound (A12B4C3) that is a noncompetitive but specific binder of
Kelley et al. Page 13
Future Oncol. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
PNKP. Cell studies indicate that A12B4C3 is a chemosensitizer to topoisomerase inhibitors
[98].
Patients with intrinsically low levels of Ligase IV are radiosensitive. The one inhibitor being
tested preclinically against it is SCR7; it appears to selectively interfere with Ligase IV–
DNA binding [95]. Such disruption in sealing DSBs leads to accumulation of unrepaired
breaks, activation of ATM and, ultimately, an intrinsic pathway of apoptosis. Other potential
Ligase IV inhibitors have been modeled in silico [99]. See Table 7 for more details of all
these inhibitors in development.
DNA inhibition as treatment for chemotherapy-induced peripheral
neuropathy
Up to 90% of all cancer patients experience persistent chemotherapy-induced peripheral
neuropathy (CIPN) [100,101]. The severity of CIPN can result in treatment delays, dose
modifications or discontinuation of antineoplastic drugs [100,102]. A `perfect storm' of
factors makes sensory neurons especially susceptible to damage: they are nondividing cells
with high metabolic activity; by residing outside of the blood-brain barrier, they are exposed
to higher amounts of agents that cause oxidative stress or direct DNA damage; and gene
transcription and translation are much higher in neurons than other cells, so damage to
mitochondrial DNA is particularly harmful to neurons. Collectively, this makes neurons
very susceptible to functional damage [100,103].
Many potential treatments for CIPN, including antiepileptics and antidepressants, have had
little to no effect in alleviating CIPN's symptoms, let alone reversing neuronal damage.
Inconclusive or limited evidence exists for the efficacy of topical anesthetic creams,
antioxidants, nutraceuticals, certain ion channel modulators or modalities (acupuncture,
magnetic stimulation and electrostimulation) [100–101,104–105].
However, molecular characterization of how DNA-damaging agents affect neurons can
reveal how to treat CIPN effectively [100,106]. Interestingly, the primary repair pathways in
peripheral nerves are NER and BER [107–109]. Recent evidence suggests that modifying
DNA repair pathways in CIPN models has an effect on a variety of neuropathic markers.
Downregulation and inhibition of DNA repair elements may have adverse effects on sensory
neurons [110] – but selectively upregulating a DNA repair protein could possibly alleviate
CIPN.
Evidence for this exists in multiple forms. For example, in mouse models, the significant
increase in thermal and nociceptive responses from oxaliplatin can be prevented by
administration of antioxidants (flavonoids) [111]. The severity of CIPN correlates with
dosing of platinating agents when NER is dysfunctional: mice deficient in XPA and XPC
accumulate more platinum adducts in sensory neurons than wild-type mice given the same
cisplatin dose [112]. However, cisplatin-induced increases in cell death and decreases in
capsaicin-evoked release of CGRP in sensory neuronal cultures can be attenuated by
overexpression of repair-competent APE1, an important BER endonuclease [113]. Other
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studies indicate that selectively enhancing the repair function BER's endonuclease, APE1,
can prevent or alleviate CIPN [106].
However, modulating DNA repair components is not a clear-cut issue of selective
upregulation. Inhibition of certain DNA repair elements may actually have a positive effect
on sensory neurons. In a mouse model, concurrent administration of cisplatin or oxaliplatin
with an experimental PARPi (Compound 4a) attenuated allodynia and hyperalgesia [114].
However, PARP may interfere with the activity of APE1 when significant DNA damage is
present [115]. Additionally, PARP expression can stimulate or inhibit many hallmarks of
cancer besides DNA repair [15].
The ongoing challenge is to find a laser focus for ameliorating CIPN without increasing
tumor cells' survival capabilities. Modulation of DNA repair elements to treat CIPN is an
emerging field. Ongoing studies are investigating diagnostic markers, molecular
mechanisms, drug comparisons and potential treatments for CIPN [116–118]. Development
of an effective small-molecule DNA repair inhibitor would be a first-in-class drug for
neuropathic pain, which could change both survival and quality-of-life outcomes for many
cancer patients.
Changing face of R&D in DNA repair inhibition
The potential clinical utility of DNA repair inhibitors is attractive, so several companies
solely focused on DNA repair inhibition have emerged in recent years. Here are the ones
that have been in the news for their research.
Inotek Pharmaceuticals Corporation (MA, USA; and Israel) is working to produce a line of
PARPis, which are in late preclinical stages of development [119]. Its pipeline also includes
a reactive oxygen species inhibitor and other classes of investigative drugs.
ApeX Therapeutics (IN, USA) is developing inhibitors to the DNA repair protein Ref1/
Ape1, to treat cancers as well as other diseases involving pathological neovascularization
[52]. It has several inhibitors in late preclinical development.
Tracon Pharmaceuticals (CA, USA) has three Phase I trials in progress for its lead
compound, TRC102, which is showing promise in reversing BER-generated resistance to
alkylator and antimetabolite chemotherapy. In addition, Tracon is developing TRC105, an
antiangiogenic monoclonal antibody being tested as both monotherapy and combination
therapy for a variety of solid tumors as well as macular degeneration (Phase I and II clinical
trials) [120].
Sentinel Oncology (Cambridge, UK) is developing highly selective CHK1 and PI3K-mTOR
inhibitors, as well as a `targeted synergy' vehicle for delivering and specifically activating
drugs in the hypoxic microenvironment uniquely found in solid tumors [121].
The DNA Repair Company (MA, USA) is profiling all DNA repair pathways in tumor
samples from registries. By determining which pathways are `on' or `off', they are
generating antibodies that can be used in the future to test patients to determine what drugs
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they will most likely respond to. The company's longer-range goal is to screen for small-
molecule inhibitors of all DNA repair pathways [122].
Mission Therapeutics (Cambridge, UK) concentrates on the `backside' of DNA damage
response and repair: ubiquitination and related processes. In certain cancers, mutations in
genes or activation of oncogenes (e.g., c-myc) prevent cells from disposing of misfolded or
damaged proteins; the concentration of proteins involved in the cell cycle is also deregulated
[123]. Among the dozen potential targets of ubiquitin inhibition that Mission Therapeutics is
investigating are E2 conjugating enzymes, which affect the cyclins involved in cell cycle
checkpoints, p53 (a tumor suppressor protein) and NF-κB (the transcription factor involved
in inflammation and immune responses) [124]. E2s are relatively nonspecific, have many
yet-unstudied functions and are not classically druggable (therefore, difficult to inhibit).
Despite those challenges, the reversible process of ubiquitination makes inhibition of
deubiquitinating enzymes a tantalizing target [123].
It is interesting that this is relatively short list. However, research efforts with DNA repair
inhibitors within large multidivision pharmaceutical companies remain publicly unknown.
Future perspective
Emerging methods of molecular analysis to better manage a patient's disease or
predisposition to disease are moving us closer to the reality of truly personalized medicine.
Concurrent development of DNA repair inhibitors and companion testing for their targets is
growing. In just the past 2 years, the FDA approved four cancer drugs for use in patients
whose tumors have specific genetic characteristics that are identified by a companion
diagnostic test [125].
Finding specific biomarkers poses multiple challenges because variant alleles may create
different effects, based on tumor types, patient populations, treatment regimens and different
stages of illness. Testing altered gene expression plus compensatory mechanisms can more
accurately convey DNA repair activity in a given tumor [126].
Sifting through such massive data to determine whether a particular gene, its upstream
regulators or mediators, or SNPs are clinically relevant as prognostic or predictive
biomarkers is a daunting task. Next-generation genomic sequencing and accelerated data
analyses of cancer tissues are providing ways to identify the molecular drivers of individual
tumors. In the USA, Foundation Medicine [127] is doing that to provide actionable genomic
information for physicians in choosing optimal treatments for individual tumors. Building a
repository of such information may uncover new biomarkers as well as identify off-label
treatments that could work when others fail (or when conventional treatment options are
limited, such as with rare cancers).
On the international front, efforts such as the Gene-PARE project are underway. By
analyzing its huge biorepository, it can validate tests that can predict which patients with
specific genetic variants would be most likely to develop adverse responses to radiation
treatment [128].
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To offer widespread benefit, biomarker tests need to be reliable, readily available, able to be
run using existing clinical laboratory technology [126], and fast enough to provide a timely
turnaround without delaying the start of treatment. Advanced screening procedures and
more careful selection of patient cohorts for clinical trials will help ensure that the outcomes
of those trials accurately reflect the selected intervention's anticancer capabilities.
In the near future, comprehensive molecular characterization of DNA repair proteins will
provide greater understanding of the crosstalk between DNA repair functionality and genetic
stability. The REPAIRtoire database seeks to facilitate this. It is the first database of its kind
to categorize all DNA repair proteins and repair intermediates, all diseases associated with
DNA defects, all known DNA lesions linked to environmental mutagenic and cytotoxic
agents, and all transformations that occur during the DNA damage response and repair
process [129].
Better characterization of DNA repair proteins will lead to discoveries of more effective
repair inhibitors and more efficient cancer-killing, synthetically lethal therapeutic
combinations. Highly localized radiotherapy will also play an increasing role in combination
or sequential treatment. For example, sequential treatment of multiple myeloma with a
thymidylate synthase inhibitor followed by nanoirradiation by an Auger electron-emitting
thymidine analog shows promise in eradicating multiple myeloma stem cells [130].
Also, treatment regimens will be more finely tuned to the stage of cancer. For example, as
cancer progresses, its microenvironment becomes hypoxic, causing replicative stress,
disrupting DNA synthesis and downregulating DNA repair [76], which makes cancer cells
increasingly prone to DNA mutations. Thus, in advanced cancers, checkpoint inhibitors may
be more effective than DNA repair inhibitors. Interestingly, chronic hypoxia often makes
tumors more sensitive to radiotherapy [131].
Pinpointing what treatments will work best and when presents both opportunity and
challenge: researchers must demonstrate not only that inhibitors are safe as single agents,
but also that they augment DNA damage when given with chemotherapy or radiotherapy.
After the efficacy of combination therapy is established in preclinical studies, the proper
dosing and regimen in clinical trials is crucial to determine. With the addition of DNA repair
inhibitors, standard chemotherapy could become more effective but also more toxic. The
ultimate goal would be to be able to reduce the dose of chemotherapy in combination with
DNA repair inhibitor and achieve more profound effects on tumor regression. Finding ways
to fast-track combination-treatment clinical trials will be imperative in bringing discoveries
from bench to bedside [24]. From an economic standpoint, researchers will also be
increasingly involved in showing how the development of DNA repair inhibitors is highly
effective stewardship of R&D resources and patient expenses [132].
Cancer cells can overcome genotoxic effects in at least three ways: by compensatory DNA
repair mechanisms, by developing damage tolerance; and/or by reversing a genetic or epi-
genetic defect. Epigenetic research is just starting to scratch the surface of the potential for
more options for DNA repair inhibition, such as hyper- or hypo-methylation of gene
promoters [131]. In the next 5–10 years, many relevant discoveries regarding cancer's
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behavior, thus, treatment are expected to emerge from epigenetic studies. In the meantime,
intense research efforts to develop DNA repair inhibitors continue (Figure 1).
Conclusion & future perspective
Research and clinical trials have validated the therapeutic importance of using specific DNA
inhibitors, primarily in combination with DNA-damaging drugs. Unanticipated issues can
occur when trying to directly inhibit steps in some DNA repair pathways, but a greater
understanding of pathway crosstalk is leading to `back-door' routes of inhibition. Globally,
perhaps the biggest technical challenge in developing DNA repair inhibitors is target
specificity, as a repair protein's active sites are often relatively small and are buried deep
within the protein's tertiary structure [33]. In some cases, inhibitory binding to regions
outside of the catalytic site can also modulate protein function, and some next-generation
inhibitors (particularly kinase inhibitors) are seeking to exploit such divergent binding
pockets. To provide the greatest therapeutic benefit from these therapies, the development of
biomarkers is crucial in helping establish which patient populations are candidates for, and
will respond best to, use of DNA repair inhibitors as part of their therapeutic regimen. The
concurrent development of DNA repair inhibitors and biomarkers will enable earlier
detection and treatment of cancers and will move us closer to delivering truly personalized
medicine.
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Box 1. MGMt inhibitors in development and clinical use
Function(s)
• Removes alkyl groups from the O6 position of guanine, and, to a lesser extent,
the O4 position of thymine
Why it is a good target for inhibition
• A discrete protein with a highly specialized function in one repair pathway
• Methylating MGMT's gene promoter sensitizes cells to alkylating agents and IR
• Related: MGMT methylation status appears to be a good prognostic biomarker
Challenges
• MGMT inhibition affects both healthy cells and tumor cells
• MGMT levels vary greatly among cancers and even within tumor cells
• MGMT inhibition does not work if a deficiency exists in the MMR pathway
• Other pathways can repair methylating damage in the absence of MGMT
Compounds being investigated
• In clinical use: O6-BG; first drug developed as a chemosensitizer
• In clinical trials: O6-BG + many other drug combinations; PaTrin-2
• Under investigation: oncolytic viruses; extended low-dose TMZ (an alkylator)
to deplete MGMT levels before administering standard-dose TMZ
• Other notes: KU-60019 turned out to be a checkpoint (ATM/ATR) inhibitor
IR: Ionizing radiation; MMR: Mismatch repair; O6-BG: O6-benzylguanine; PaTrin-2:
O6-(4 bromothenyl)guanine; TMZ: Temozolomide. Adapted with permission from [28].
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EXECUTIVE SUMMARY
Inhibition & synthetic lethality
• Development of DNA repair inhibitors is a burgeoning field of research.
• Currently the most widely used DNA repair inhibitors block steps in the direct
repair and base excision repair pathways.
Overview of each pathway & inhibitors in development
• Multiple targets for DNA repair inhibition are discussed, as well as challenges
and lessons learned in their development.
• Pathway crosstalk, overlap and multifunctional proteins complicate the
development of DNA repair inhibitors, but also provide opportunities for wider
application, such as the tremendous success seen with PARP inhibitors.
• Counterintuitively, the proficiency of some DNA repair pathways helps ensure
sensitivity to chemo- and radio-therapeutics; for example, an intact mismatch
repair pathway increases cells' sensitivity to many chemotherapeutics by 2–100-
fold.
• Although direct inhibition of a repair pathway is not always feasible, indirect
inhibition and creating synthetic lethalities can be effective. Both approaches are
discussed in this review.
Changing face of R&D in DNA repair inhibition
• Concurrent development of biomarkers for cancers will aid in earlier detection
and more effective treatment planning.
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Figure 1.
current targets of nuclear DNA repair pathway proteins and their functions.
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Table 1
Overlap and crosstalk among DNA repair pathways.
Pathway Backup Type of problem/provision for repair
DR MMR If MGMT fails to remove O6-methylguanine, the MMR pathway can recognize and fix O6-methylguanine misspairs
MMR MMR can repair postreplicative guanine/thymine mismatches
Futile MMR cycles create DSBs, which either induces apoptosis or activate repair by HR or NHEJ
NER NER can repair larger adducts at the O6 position of guaninethat MGMT cannot repair
BER BER can repair mismatch pairs and other alkylation adducts that DR does not repair
BER NER NER can serve as a backup for repairing minor oxidative damage
HR If BER does not repair ssDNA breaks, they may lead to DSBs, which HR can repair
HR/NHEJ If BER fails to repair SSBs, HRcan repair them during replication (S phase). If signaling arrests the cell cycle at G1,
then NHEJ can repair the breaks
NHEJ HR HR can repair DNA DSBs that the NHEJ pathway fails to process
BER: Base excision repair; DR: Direct repair; DSB: Double-stranded break; HR: Honnologous reconnbination; MMR: Misnnatch repair; NER:
Nucleotide excision repair; NHEJ: Nonhonnologous end joining.
Data taken from [6].
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Table 2
Clinical trials in progress for PARP inhibitors.
Compound (alt. name) Manufacturer Clinical
trials in
progress
Targeted cancers NCT identifiers
Iniparib (SAR240550, BSI-201) Sanofi-Aventis Phase I Brain metastases,
advanced solid tumors
NCT01551680, NCT01213381
Phase II Primary and metastatic
breast, advanced or
recurrent uterine, stage
IV NSCLC
NCT01045304, NCT00687687, NCT01086254
Phase III Metastatic TNBC NCT00938652
Olaparib (AZD2281, KU-0069436) AstraZeneca Phase I Ovarian, fallopian
tube, breast, HER and
PR breast, metastatic
TNBC, pancreatic,
advanced and
metastatic solid
tumors, melanomas,
Ewing's sarcoma
NCT00516373, NCT00707707,
NCT00516724, NCT00515866, NCT00516802
Phase II Breast, HER and PR
breast, ovarian,
fallopian tube,
prostate, gastric,
colorectal, Ewing's
sarcoma
NCT00494234, NCT01116648,
NCT00679783, NCT01078662, NCT01583543
Phase III Platinum-sensitive,
BRCA-mutated,
relapsed ovarian
NCT01874353
Niraparib Tesaro Phase III Platinum-sensitive
ovarian, HER2,
BRCA-mutated, breast
NCT01847274
Rucaparib (CO-338, AG-014699,
PF-O1367338)
Pfizer Phase I Advanced solid tumors NCT01009190
Phase II Primary and metastatic
breast and ovarian,
BRCA-mutated,
fallopian tube,
peritoneal
NCT00664781, NCT01074970, NCT01482715
Phase III Ovarian, fallopian
tube, peritoneal
NCT01968213
Veliparib (ABT-888) Abbott Phase I BRCA-mutated,
numerous leukemias,
lymphoma,
medulloblastoma,
pontine glioma,
ependymoma,
astrocytoma, advanced
solid tumors,
numerous stage II–IV
gynecological and
peritoneal cavity
cancers, TNBC,
gastric, locally
advanced rectal,
metastatic melanoma
NCT01853306, NCT00740805,
NCT00946335, NCT01514201,
NCT01123876, NCT01063816,
NCT01434316, NCT01749397,
NCT01145430, NCT01012817,
NCT00989651, NCT01589419, NCT01366144
Phase II Breast, metastatic
breast, TNBC, ovarian,
fallopian tube, BRCA-
mutated, colorectal,
non-Hodgkin's
NCT01149083, NCT01506609,
NCT01009788, NCT01306032,
NCT01540565, NCT01690598,
NCT01051596, NCT01326702,
NCT01489865, NCT01585805
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Compound (alt. name) Manufacturer Clinical
trials in
progress
Targeted cancers NCT identifiers
lymphoma, metastatic
pancreatic, recurrent
NSCLC, primary
peritoneal
AZD2461 AstraZeneca Phase I Refractory solid
tumors (activity
against olaparib-
resistant tumors)
NCT01247168
BMN673 BioMarin Pharmaceutical Phase I AML, CLL, mantle
cell lymphoma,
myelodysplastic
syndrome, advanced
solid tumors, NSCLC,
prostate, pancreatic
NCT01399840, NCT01989546, NCT01286987
Phase III Breast, BRCA-mutated NCT01945775
CEP-9722 Cephalon Phase I Mantle cell lymphoma,
advanced solid tumors
NCT01345357
E7016 Esai Phase I Advanced solid tumors NCT01127178
Phase II Stage III and IV
melanoma
NCT01605162
INO-1001 Inotek Pharmaceuticals Phase I Melanoma NCT00272415
MK-4827 Merck Phase I Advanced solid
tumors, CLL, T-cell-
prolymphocytic
leukemia
NCT0079502
Methoxyamine Sigma Aldrich Phase I Numerous lymphomas NCT01658319
PARP inhibitor clinical trials in progress as of Novennber 2013: 115 (status is unknown on some trials; those were not included in this total).
alt: Alternative; AML: Acute myelogenous leukemia; CLL: Chronic lymphocytic leukemia, NSCLC: Non-small-cell lung cancer; TNBC:Triple-
negative breast cancer.
Data taken from [11].
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Table 3
Base excision repair inhibitors in development and clinical use.
BER protein Function(s) Rationales for inhibiting Challenges Compounds being investigated
APE1 Repair: prepares AP
site to receive new
nucleotide(s)
Redox: maintains
genes in their active,
reduced state
Overexpressed in many cancers
Associated with resistance to alkylating
and oxidizing agents
No substitute exists for this protein
Achieving
specificity to
solely inhibit the
repair or redox
function
Repair:
• Nonspecific: methoxyamine
(binds to the aldehyde in the AP
site of DNA); lucanthone
• Specific: AR03; lnhibitor-1;
ML-199 and analogs
Redox:
• E3330and analogs
Pol β Resynthesizes
nucleotides
Removes certain
blocking residues
A rate-limiting step in BER Often
overexpressed in tumor cells
Associated with resistance to IR,
bleomycin, some alkylating agents,
cisplatin
Difficult to
develop an
inhibitor specific
to the polymerase
domain that would
not also inhibit
polymerases
involved in DNA
replication
Inhibiting its lyase
function may be
more lucrative
>60 inhibitors identified; most
lack specificity
Most promising so far (cell
studies only):
• Oleanolicacid
• Edgeworin
• Betulinic
• Stigmasterol
•NCS-666715
•NSC-124854
FEN1 Progressivity factor
Helps polymerases
synthesize
nucleotides
efficiently and
accurately
Elevated in many cancers Inhibition
creates unligatable DNAand makes cells
hypersensitive to alkylating agents
Importance of
protein in pathway
could prove
difficult in
identifying
inhibitors with
lowtoxicity to
normal cells
Afewhydroxyurea-based FEN1
inhibitors (cell studies only)
PARP1 Surveillance/damage
sensor
Assesses extent of
damage; determines
whether to signal
apoptosis Helps
decondense
chromatin
Recruits repair
proteins to the
damage site
Facilitates repairs
Uses NAD+to transfer ADP-ribose
polymers onto specific acceptor proteins
including itself; this modifies the
protein's properties Although not
essential to BER, PARPI's absence
causes an accumulation of DNA damage
that certain cancers cannot repair
Inhibitors potentiate the effects of
alkylating agents, platinating agents,
topoisomerase 1 poisons, IR
Secondary
mutations can
correct for this
repair deficiency,
causing resistance
to PARPis
Already in clinical use:
• Iniparib
• Olaparib
In clinical trials:
• ABT-888
• AZD2461
•BMN673
• E7449
• INO-1001
• CEP-9722
• MK-4827
• Rucaparib
• Velaparib
• >115 clinical trials in progress
for newer-generation PARPis and
broader use of first-generation
inhibitors
Cell studies only:
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BER protein Function(s) Rationales for inhibiting Challenges Compounds being investigated
• PJ-34
•DPQ
AP: Abasic (apurinic, apyrimidinic); BER: Base excision repair; IR: Ionizing radiation; PARPi: PARP inhibitor.
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Table 4
Mismatch repair inhibitors in development.
MMR protein Function(s) Rationales for inhibiting Challenges Compounds being investigated
MLH1 Scaffolding
protein Damage
sensor Helps
determine the
specific strand
error
Can be hypomethylated to restore
functionality
Inhibition in deficient cells could
theoretically cause a synthetic
lethality
MMR deficiencies cause
or increase
chemoresistance Intact
MMR function is crucial
for proper cell cycle
checkpoint control
To restore functionality:
• FdCyd
To create synthetic lethality in
MLH1-deficient cells (cell
studies):
• Pol γ inhibitor
MSH2 Damage sensor Its damage-sensing ability can be
bypassed by inducing a synthetic
lethality
MMR deficiencies cause
or increase
chemoresistance Intact
MMR function is crucial
for proper cell cycle
checkpoint control
In clinical trials:
• Methotrexate
In MLH2-deficient cells (cell
studies):
• Pol β inhibitor
MMR: Mismatch repair.
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Table 7
Nonhomologous end joining inhibitors in development.
NHEJ protein Function(s) Rationales for inhibiting Challenges Compounds being investigated
DNA-PK Processes
incompatible
ends so they can
be ligated
Appears to be unique to
NHEJ Essential for NHEJ
activity
Increases DNA damage tolerance
Causes chemoresistance
Predisposes cells to autosomal
recessive disorders and
malignancies, especially lymphoid
cancers
Nonspecific (inhibit PI3K):
• Wortmannin LY294002 DNA-
PK-specific (cell studies only):
• NU7441
• NU7026
Phase I studies:
• CC-115
• CC-122
PNKP Processes
incompatible
ends so
nucleotidescan be
replaced and the
termini ligated
Appears to be unique to
NHEJ
Increases DNA damage tolerance
Causes chemoresistance
Predisposes cells to autosomal
recessive disorders and
malignancies, especially lymphoid
cancers
Cell studies only:
• A12B4C3
Ligase IV Seals nicks in
final repair step
A rate-limiting step Cannot
work in the absence of
XRCC4
Increases DNA damage tolerance
Causes
chemoresistancePredisposes cells
to autosomal recessive disorders
and malignancies, especially
lymphoid cancers
Murine models:
• SCR7
Indirect ways of modulating NHEJ functionality are being explored as more viable options than direct inhibition. Examples: overexpression of a
truncated form of XRCC4 can inhibit NHEJ by interfering with DNA Ligase IV; DNA-PKcs can be inhibited indirectly by inhibiting EGFR or by
inhibiting ATM (by using miRNA or small-molecule inhibitors); topoisomerase inhibitors prevent NHEJ repair proteins from gaining access to
areas of damage; and epigenetic factors (methylation of gene promoters) are under investigation as well. It is yet unknown how or if these findings
can translate into future clinical use.
NHEJ: Nonhomologous end joining.
Adapted with permission from [28].
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